About Cassipharma
Cassipharma is a private limited company (BVBA/SPRL, legacy) based in Gent, founded in 2002. Its main activity is classified as "Detailhandel in farmaceutische producten". For the 2025 financial year, Cassipharma reported a profit of €8,177. A year earlier, in 2024, it still made a loss of €15,497. Revenue was not published, which is common for abbreviated accounts. The gross margin came to €167,759, up 27% on 2024. It employed an average of 2.1 full-time equivalents. Equity stands at €217,796, a solvency ratio of 40%. In 2007 it was €380,801. 19 annual accounts are available, covering 2007 to 2025.
- Sectors
- Pharmacies
- Signals
-
ProfitableProfitable € 5K
The company reported a positive net result in the latest financial year.
Strong equityStrong equity € 218KStrong equity provides a buffer against setbacks.
Low riskLow risk 39.7%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 1.66A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 9KPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 6KPositive EBITDA: operating activities are profitable.
Healthy social debtHealthy social debt 11.1%Social debts stay manageable relative to personnel costs.
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2025
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2022
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
168K
|
€
132K
|
€
70K
|
€
274K
|
|
|
€
6K
|
€
-17K
|
€
-73K
|
€
114K
|
|
|
€
8K
|
€
-15K
|
€
-71K
|
€
52K
|
|
|
€
218K
|
€
217K
|
€
233K
|
€
720K
|
|
|
39.67%
|
39.03%
|
36.93%
|
42.42%
|
|
|
€
331K
|
€
339K
|
€
397K
|
€
977K
|
|
|
€
294K
|
€
286K
|
€
306K
|
€
441K
|
|
|
2.10
|
2.10
|
2.10
|
2.90
|
Publications 20
All publications- Ontslagen - Benoemingen - Statuten (Vertaling, Cordinatie, Overige Wijzigingen, ) - Wijziging Rechtsvorm - Rubriek Herstructurering (Fusie, Splitsing, Overdracht Vermogen, Enz...) 20/02/2023
- Rubriek Herstructurering (Fusie, Splitsing, Overdracht Vermogen, Enz...) 14/12/2022
- Me. - Jaarrekening 30.06.2016, Ggk 02.12.2016, Ngl 20.12.2016 16708-0161-016 23/12/2016
- Me. - Jaarrekening 30.06.2015, Ggk 04.12.2015, Ngl 08.12.2015 15684-0131-016 15/12/2015
- Me. - Jaarrekening 30.06.2014, Ggk 15.12.2014, Ngl 18.12.2014 14697-0230-016 23/12/2014
Frequently asked questions
Answers to the most common questions about Cassipharma, based on official government data and the filed annual accounts.
What is the VAT number of Cassipharma?
The VAT number of Cassipharma is BE0477.736.777.
How many employees work at Cassipharma?
In 2025, Cassipharma employed 2.10 full-time equivalents (FTE).
When was Cassipharma established?
Cassipharma was founded in 12-06-2002.
What is the official address of Cassipharma?
The official address of Cassipharma is Koning Boudewijnstraat 25 Gent 9000.
What is the legal form of Cassipharma?
The juridical form of Cassipharma is Private limited company (BVBA/SPRL, legacy).
What is the annual revenue of Cassipharma?
The 2025 accounts of Cassipharma do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
Is Cassipharma a reliable company?
Cassipharma is a registered Rechtspersoon with company number 0477.736.777 and can be verified through the official CBE database.
What is the credit limit of Cassipharma?
The estimated credit limit of Cassipharma is €14,877.
Is Cassipharma still active?
Cassipharma currently has the status "Normal situation" and is active.